ARTICLE | Company News

Mallinckrodt acquiring Sucampo

January 5, 2018 8:40 PM UTC

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close of $17 on Dec. 22, the last trading day before the deal was announced, and a 20% premium to Sucampo's close of $14.95 on Dec. 6, the day before a Bloomberg report said the company was considering a sale after receiving takeover interest. The deal is slated to close next quarter.

Mallinckrodt will gain two late-stage rare disease candidates -- VTS-270 and CPP-1X/sulindac...